Document is current

Article History

Received: 1 April 2024

Accepted: 7 October 2024

First Online: 8 October 2024

Declarations

:

: The protocol of this study was approved by the Institutional Review Board of Asan Medical Center(IRB No.:2023 − 1129), and it was conducted in accordance with the ethical principles of the Declaration of Helsinki and within the Good Clinical Practice Guidelines, as defined by the International Conference on Harmonization. All patients provided written informed consent before enrollment.

: Not applicable.

: There is nothing to declare that is directly related to this work. Outside this work, YKK has served as a consultant for ALX Oncology, Zymeworks, Amgen, Novartis, Macrogenics, Daehwa, Blueprint, Surface Oncology, BMS, and Merck (MSD). MHR received honoraria from DAEHWA Pharmaceuticals, Bristol Myers Squibb, Lilly, Ono Pharmaceuticals, MSD, Taiho Pharmaceuticals, Novartis, Daiichi Sankyo, and AstraZeneca, and served as a consultant for DAEHWA Pharmaceuticals, Bristol Myers Squibb, Lilly, and Ono Pharmaceuticals. CY received honoraria from Servier, Bayer, AstraZeneca, Merck Sharp & Dohme, Eisai, Celgene, Bristol Myers Squibb, Debiopharm, Ipsen, Kyowa Kirin, Novartis, Boryung Pharmaceuticals, Merck Serono, Mundipharma, Roche, and Janssen, and received research grants from Servier, Bayer, AstraZeneca, Ono Pharmaceuticals, Celgene, Ipsen, Boryung Pharmaceuticals, Ildong Pharmaceuticals, CKD Pharmaceuticals, and HK inno.N.